logo
5 Signs Your Hair Needs Help

5 Signs Your Hair Needs Help

Vogue23-05-2025
My bathroom cabinet is a mess. I've dedicated the entire space to haircare items—brushes, combs, heat protectants, serums, oils, and styling products. Still, my hair is a lot like that cabinet—a mess. Dry, brittle, untamable, and greasy all at once. What gives?
After a chat with hair specialist Helena Rodero and a thorough read of her book All About Your Hair and Skin, I've been able to pinpoint exactly what's causing my hair problems—and also, how to fix them. Turns out layering on all the hair products in the world can't fix a head that's suffering due to bad habits. Read on to find out what I learned and the top five signs your hair might need a little help, too.
Sign 1: Flakey scalp
Rodero says 'a flakey scalp' is one of the most common issues her clients complain about. It's also one of the most misunderstood: Most people think the flaking is caused by dry scalp, so they wash their hair less frequently. But this doesn't get to the root of the problem. 'Dandruff is caused by a fungus called Malassezia furfur, which lives on our scalp,' explains Rodero. 'The problem appears when the fungus increases, causing an imbalance in the microbiota and giving rise to dandruff or seborrheic dermatitis.'
Washing our hair less actually only makes it worse, because it allows the fungus to grow out of control, thus increasing flaking. 'We should wash daily or every other day—this will significantly reduce the problem,' she advises, and recommends shampoos that treat seborrheic dermatitis. These products contain ingredients that regulate sebaceous secretion up to a certain point (controlling it completely is very complicated) as well as keratolytic ingredients that help cleanse the scalp.
'The most commonly used active ingredients to treat dandruff and seborrheic dermatitis are piroctone olamine, ciclopirox olamine, selenium sulfide, and salicylic acid; They can appear alone or in combination,' Rodero explains, noting that according to clinical trials, the most effective ingredient is piroctone olamine. Look for it first in your anti-dandruff products.
Sign 2: Greasy scalp
You've probably heard that the best thing to do for oily hair is to wash it sparingly to regulate the oil, right? Wrong! Oily hair, as Rodero explains, is largely dependent on our hormones—which is precisely why it can be so complicated to control. Additionally, washing hair less can compound the problem: 'It can cause seborrheic dermatitis to appear, which is a type of dandruff that is more oily,' Robero explains. 'Then, it remains embedded in the scalp in the form of small yellow plaques.' This is why she recommends washing hair frequently instead, alternating between a shampoo for oily scalp and one that is more gentle.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is it Time to Sell UnitedHealth Group (UNH) Before its Too Late?
Is it Time to Sell UnitedHealth Group (UNH) Before its Too Late?

Yahoo

time14 minutes ago

  • Yahoo

Is it Time to Sell UnitedHealth Group (UNH) Before its Too Late?

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 Value Index, which returned 3.79% for the same period. The fund's top 5 holdings are also listed in the letter, showing the firm's main investment positions heading into 2025. One of the companies mentioned in the letter is UnitedHealth Group Inc. (NYSE:UNH). UnitedHealth Group Inc. (NYSE:UNH) operates as a health care company in the United States and internationally. Over the past month, UnitedHealth Group Inc. (NYSE:UNH) fell by -15.12%, and it went down to -54.69% over the last 12 months. On July 29, 2025, UnitedHealth Group Inc. (NYSE:UNH) shares closed at $261.07, with a market value of $236.83 billion. Here is what they have to say about UnitedHealth Group Inc. (NYSE:UNH) in their investor letter: "UnitedHealth Group declined as the company battled with the fallout of missing earnings forecasts and the abrupt resignation of Chief Executive Andrew Witty. We are optimistic that execution will significantly improve with the return of former CEO Stephen Hemsley." Is it Time to Sell UnitedHealth Group (UNH) Before its Too Late? UnitedHealth Group Inc. (NYSE:UNH) ranks 18th in our list of the 30 most popular stocks among hedge funds. According to our data, 139 hedge fund portfolios held positions in UnitedHealth Group Inc. (NYSE:UNH) at the end of the first quarter of 2025, down from 150 in the previous quarter. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. UnitedHealth Group Inc. (NYSE:UNH) ranks 18th in our list of the 30 most popular stocks among hedge funds. According to our data, 139 hedge fund portfolios held positions in UnitedHealth Group Inc. (NYSE:UNH) at the end of the first quarter of 2025, down from 150 in the previous quarter. While we acknowledge the risk and potential of UNH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than UNH and that has 10,000% upside potential, check out our report about this cheapest AI stock. In another article, we covered UnitedHealth Group Inc. (NYSE:UNH) and Barclays analyst Andrew Mok's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Yahoo

time14 minutes ago

  • Yahoo

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference, being held on August 12-14, 2025 in Boston, MA. Date: Wednesday, August 13, 2025Time: 2:00-2:25PM ESTWebcast Link: Canaccord Genuity / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on A replay of the webcast will be archived for up to 90 days following the session date. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). In May 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company's platforms; and expectations regarding the potential benefits conferred by Regenerative Medicine Advanced Therapy Designation, Fast Track Designation, Orphan Drug Designation or Orphan Designation. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor ContactTheodore JenkinsVice President, Investor Relations and Business DevelopmentCandel Therapeutics, Media ContactBen ShannonVice PresidentICR Healthcare CandelPR@ produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información

Beyond The Merger: A Data-Driven Playbook For Healthcare Integration
Beyond The Merger: A Data-Driven Playbook For Healthcare Integration

Forbes

time17 minutes ago

  • Forbes

Beyond The Merger: A Data-Driven Playbook For Healthcare Integration

Dave Albano, President of has more than 35 years of technology industry leadership experience. Mergers and acquisitions (M&As) are accelerating across healthcare—combining hospitals, physician groups, payers and digital health platforms in pursuit of scale, integrated care and better financial performance. However, the value of these deals often hinges on something far less glamorous: how quickly and securely the combined organization can merge and unlock value from inherited data. Meanwhile, M&A is a stress test across three critical domains: • Operational systems—from EHRs to scheduling tools—must be integrated to avoid disruption to patient care and clinician workflows. • Financial systems must be reconciled to ensure billing, revenue cycle management and forecasting remain accurate across legacy platforms. • Compliance requirements must be maintained across both entities, even as policies, access controls and reporting obligations shift under new ownership. In short, M&As create a perfect storm of fragmented systems, increased regulatory scrutiny and pressure to deliver value fast. The Post-M&A Data Landscape With each merger, multiple EHRs, claims systems, analytics tools and governance frameworks converge. This introduces a new layer of complexity, as most systems were built in isolation and weren't designed to talk to each other. Even beyond infrastructure, the business logic within these systems often diverges. Definitions for metrics like "encounter," "denial" or "readmission" can vary significantly. Getting to a shared view of operational performance, financial health and patient outcomes takes more than mapping data fields; it requires reconciling business processes and compliance assumptions. Timelines for these efforts are frequently underestimated. Data unification delays can stretch 12 to 18 months post-close, stalling the very efficiencies the deal was meant to unlock. To avoid these slowdowns, many leading organizations are investing early in centralized data repositories that unify fragmented pipelines, normalize definitions and support near real-time reporting across all departments. Non-Negotiables: Security And Compliance Healthcare data is highly regulated, and M&A activity intensifies those obligations. New data sharing workflows, unfamiliar vendors and transitional access permissions all increase exposure to security and privacy risks. Regulatory requirements such as HIPAA, HITECH and FTC breach notification rules remain in full effect during integration. In addition, state-level privacy laws like the California Consumer Privacy Act (CCPA) or others may apply depending on the entities involved. One common blind spot is user access. Orphaned accounts, inconsistent MFA enforcement and misaligned role definitions can allow unauthorized access to systems or data. Without a rapid, coordinated review of identity and access controls, the merged organization may be out of compliance from day one. The goal isn't just passing an audit. It's building trust with regulators, partners and patients. Organizations that succeed in this phase standardize identity governance across systems, implement centralized audit logging and surface compliance metrics in real time—turning regulatory risk into a managed, measurable process. Operational Challenges Beyond compliance, M&A introduces significant operational pressure. Redundant data pipelines, mismatched formats and unclear lineage slow everything from scheduling and claims to reporting and analytics. Many mid-market organizations rely on a patchwork of point tools or manual workflows—systems that may have worked before the merger but don't scale well under the increased load. The result is duplicated effort, more room for error and difficulty reconciling key performance indicators across the new entity. Even minor inconsistencies in data flows can impact clinical decisions, delay reimbursements or skew forecasts. Business continuity depends on information being not only available but also accurate, consistent and timely. Talent, Turnover And The Mid-Market Gap Post-merger environments often experience talent attrition and shifting roles. Institutional knowledge may walk out the door, and already lean teams are asked to do more with less—sometimes using unfamiliar systems. For mid-sized healthcare organizations, this is a major constraint. Teams can't rely on deep benches of engineers or expensive consultants to carry the weight of integration. That's why scalable, user-friendly platforms—designed around real workflows and supported by continuous feedback loops—are critical to long-term success. When systems are intuitive, front-line adoption increases, training costs fall and institutional knowledge is more easily retained. Bringing Order To The Chaos While no two mergers are alike, successful integrations share a common foundation—a focus on secure, scalable and efficient data unification. Prioritizing the following steps can help organizations avoid disruption, reduce risk and accelerate time to value: 1. Map what you have. Lay the foundation for trust and interoperability. Start by cataloging systems, data sources and access points across both organizations. Identify sensitive data, understand where it resides and how it's currently used. 2. Unify access and oversight. Establish governance that spans the new enterprise. Align access controls using role-based permissions. Ensure governance policies span all environments, including cloud and on-premises systems. 3. Enable seamless data flow. Support clinical accuracy and operational speed. Facilitate timely data exchange between systems to avoid discrepancies or duplication. Ensure updates to records are reflected everywhere they're needed. 4. Monitor critical workflows. Stay ahead of potential disruptions. Implement visibility into key workflows like ETL pipelines and reporting jobs. Early detection of delays or failures prevents downstream disruptions. 5. Automate where you can. Reduce manual effort and strengthen compliance. Use automation to support consistency—especially around access provisioning, audit logging and enforcement of compliance policies. This helps mitigate staffing gaps and reduces manual overhead. M&As can be transformative—but only if the underlying data and systems are securely and intelligently integrated. For healthcare organizations, this isn't just about operational alignment; it's about ensuring continuity of care, protecting patient trust and meeting the regulatory demands that govern the industry. Post-M&A integration must go beyond technical compatibility. It requires creating a unified view of operational and clinical data, delivering real-time insights to front-line care teams and embedding a culture of data-driven decision making from the C-suite to the clinic floor. That means automating manual processes, eliminating data silos and building scalable systems that support care delivery as much as they support compliance and financial stewardship. When done right, integration becomes more than a back-office function—it becomes a driver of better outcomes, faster decisions and more resilient care networks. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store